Evofem Biosciences has been granted a patent for a method and composition that combines contraception and microbicide to prevent pregnancy and reduce the risk of sexually transmitted diseases. The innovative formula includes specific compounds and an acidic carrier to enhance efficacy. GlobalData’s report on Evofem Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Evofem Biosciences, Nanoparticle drug conjugates was a key innovation area identified from patents. Evofem Biosciences's grant share as of May 2024 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US11992472B2) discloses a method for preventing pregnancy by intravaginally administering a unique composition to a subject. The composition includes a matrix-forming compound such as alginic acid, chitosan, gellan gum, or poloxamer, along with a bioadhesive compound, L-lactic acid, and an aqueous-based pharmaceutically acceptable carrier. This composition transitions from a nonmatrix state to a matrix state upon contact with ejaculate, effectively preventing pregnancy. Importantly, the total lactic acid in the composition is not in the form of a racemic mixture, enhancing its contraceptive properties.
Furthermore, the composition may also contain a humectant like glycerol, polyethylene glycol, or sorbitol, and a preservative such as benzoic acid or chlorhexidine. The method specifies various percentages of the matrix-forming compound, bioadhesive compound, and L-lactic acid in the composition, as well as the pH range required for efficacy. The composition in its matrix state is designed to trap and inactivate or immobilize sperm, providing a reliable contraceptive effect. Dosage recommendations for administration range from about 1 to 10 grams, with specific ranges outlined for optimal effectiveness. This patented method offers a novel approach to contraception through a carefully formulated intravaginal composition that acts upon contact with ejaculate to prevent pregnancy effectively.
To know more about GlobalData’s detailed insights on Evofem Biosciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
